The HPV vaccine prevents infection with the high-risk HPV strains responsible for approximately 70 percent of all cervical cancers, primarily HPV 16 and HPV 18. Cervical cancer is the second most common cancer in Indian women. Vaccination before first sexual exposure provides the strongest protection and is most effective between ages 9 and 14. Vaccinated women still require regular cervical screening because the vaccine does not cover all oncogenic HPV strains and provides no protection against HPV infection acquired before vaccination.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“The HPV vaccine is one of the few interventions in oncology that actually prevents cancer rather than treating it. The challenge in India is that too many eligible girls are missing it and too many vaccinated women think they no longer need Pap smears.”

The vaccine works by generating antibodies against specific HPV strains before exposure occurs, preventing the persistent infection that drives cervical precancer and cancer development.

• Targets High-Risk Strains: HPV 16 and HPV 18 together cause approximately 70 percent of all cervical cancers and uterus and cervical cancer prevention at the population level depends on achieving high vaccination coverage against these two strains specifically rather than against HPV infection broadly.

• Most Effective Before Exposure: The vaccine produces optimal antibody response when given before first sexual activity, which is why the primary target age is 9 to 14 years and effectiveness drops significantly in women who have already been exposed to the strains the vaccine covers.

• Three Vaccines Available in India: Cervarix covers HPV 16 and 18. Gardasil 4 adds HPV 6 and 11. Gardasil 9 covers nine strains including additional high-risk types and offers the broadest protection currently available against both cervical cancer and other HPV-related cancers.

• Screening Still Required: Even fully vaccinated women require cervical screening from age 21 to 25 because the vaccine does not cover all oncogenic strains and protects only against new infection, meaning women with prior HPV exposure remain at risk for that specific strain.

Vaccination and cervical screening are complementary strategies. Neither replaces the other in a comprehensive cervical cancer prevention programme.

Age at vaccination and prior HPV exposure determine how much protection the vaccine provides in any individual.

• Primary Target Group: Girls aged 9 to 14 receive the strongest immune response and maximum cancer prevention benefit with a two-dose schedule and robotic cancer surgery for cervical cancer is far less likely to be needed in populations with high HPV vaccination coverage in adolescent girls.

• Women 15 to 26: A three-dose schedule is recommended for women in this age group who have not been previously vaccinated, accepting that some prior HPV exposure may have occurred and that the vaccine still provides meaningful protection against strains not yet encountered.

• Women 27 to 45: Vaccination is available and discussed with a doctor on a case-by-case basis. Benefit is lower because prior HPV exposure is more likely but protection against strains not yet encountered remains clinically meaningful for some women in this age group.

• Boys and Men: HPV vaccination in males prevents HPV transmission, protects against penile, anal and oropharyngeal cancers caused by the same high-risk strains and contributes to population-level herd protection that reduces HPV prevalence in women.

HPV vaccination prevents cancer at source and for more on navigating cancer decisions with specialist input, our blog on second opinion in cancer diagnosis covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to cervical cancer surgery including robotic-assisted radical hysterectomy and lymph node dissection at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with abnormal cervical screening results, HPV-related disease or confirmed cervical cancer are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — HPV Vaccines and Cervical Cancer
2. World Health Organization — Human Papillomavirus and Cervical Cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Multivisceral resection (MVR) is a complex, en bloc surgical procedure that removes a primary cancerous tumor along with one or more adjacent organs or tissues that have been invaded. Used primarily for advanced (T4) cancers most commonly colorectal, pancreatic, or gastric it aims for curative (R0) resection where complete removal was previously thought impossible. 

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “leaving an involved organ behind to make the operation easier is not actually easier for the patient. An incomplete cancer resection rarely changes the disease course in their favour.”

The operation looks different in every case but the governing principle stays fixed regardless of which organs end up being removed.

• En Bloc Removal: The tumour and every invaded adjacent structure come out as one connected piece, not separated and removed individually. Cutting through the point of invasion to remove organs separately risks leaving cancer cells precisely where the operation was meant to clear them.
• Which Organs Get Removed: Colorectal cancers growing into the bladder or uterus, gastric cancers reaching the spleen or pancreas tail, and pelvic tumours involving multiple adjacent structures are the most common scenarios where laparoscopic cancer surgery or open multivisceral resection becomes the plan.
• Reconstruction in the Same Session: Removing multiple organs creates defects that need repair before the patient leaves theatre. Bowel joins, urinary diversions and soft tissue coverage are all planned before the patient goes to the operating table.
• Long Operating Time: These procedures typically run six to ten hours and require a team experienced across multiple organ systems. A single specialist in one anatomical area isn’t the right surgeon for this operation.

Patient fitness, tumour extent and the realistic prospect of clear margins all determine whether the tumour board recommends this approach or a different one.

The decision is never made lightly because the procedure carries real physiological burden and only makes clinical sense in specific circumstances.

• Locally Advanced Without Distant Spread: When a tumour has grown directly into a neighbouring organ but hasn’t reached distant sites, removing both structures together offers a genuine chance at curative resection. That window closes if distant metastases are present.
• Clear Margins Are Achievable: The entire point of the operation is complete tumour clearance. If the team believes clear margins across all removed structures are possible, the complexity is justified. If they’re not achievable even with multivisceral resection, the risk calculation shifts considerably.
• Patient Can Tolerate It: Six to ten hours of surgery followed by recovery from multiple organ removal demands good baseline fitness. Someone too frail or malnourished going in will not recover well regardless of how cleanly the operation goes, and robotic cancer surgery techniques at high-volume centres are increasingly applied in selected cases where minimally invasive approaches reduce the physiological burden.
• Tumour Board Consensus: No single surgeon decides to proceed with multivisceral resection alone. The full team reviews the case, the imaging, the fitness assessment and the realistic oncological benefit before any patient is listed for this operation.

Every multivisceral resection decision goes through full tumour board discussion first, and for more on how complex cancer surgery decisions are made, our blog on minimally invasive cancer surgery covers surgical approaches in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to complex multi-organ cancer resections across colorectal, gastric, gynaecological and retroperitoneal cancer types. He heads Oncology Services across Karnataka and leads cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with locally advanced cancers invading adjacent structures are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Cancer Surgery
2. National Institutes of Health — Multivisceral Resection in Oncology

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

A surgical margin is the rim of normal, healthy tissue surrounding a removed tumor, analyzed by a pathologist to determine if all cancer was successfully excised. Negative margins mean no cancer cells are at the edge, indicating complete removal, while positive margins show cancer at the edge, often requiring further surgery to reduce recurrence

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “the margin result tells us whether we actually achieved what we went in to do. It’s the most direct measure of whether a cancer operation succeeded oncologically.”

Pathologists report margins in specific categories and each one carries a different clinical implication for the next step.

• Clear Margin: No cancer cells at the edge of the removed tissue. This is the target for every cancer resection and when it’s achieved the operation is complete from an oncological standpoint without the patient needing to return for more surgery.
• Close Margin: Cancer cells sit very near the edge but don’t reach it. What counts as too close varies by cancer type — breast cancer treatment guidelines define acceptable margin width differently from colorectal or head and neck guidelines.
• Positive Margin: Cancer reaches the edge of the specimen, meaning the tumour may not have been completely removed. Re-excision to take more tissue is typically recommended unless the risks of repeat surgery outweigh the benefit for that specific patient.
• Margin Width: Even within clear results, width matters. A 2mm clear margin gives more confidence than a 0.5mm one in the same cancer type, which is why surgeons aim for the widest clear margin the local anatomy and function permit.

Pathology measures and reports margins according to the cancer type and the surgical team interprets those numbers within the full clinical picture before deciding what comes next.

A positive or very close margin doesn’t mean the operation failed but the treatment plan needs to continue rather than stop at surgery.

• Re-excision: Returning to theatre to remove more tissue from the affected area is the most straightforward response. For lumpectomy this typically means a wider local excision booked as soon as healing from the first operation allows.
• Radiation Instead: Where re-excision would significantly compromise function or appearance, radiation to the operative site addresses residual microscopic disease without a return to theatre. The oncology team decides which approach produces better overall outcomes.
• Mastectomy After Lumpectomy: When clear margins can’t be achieved through re-excision, conversion to mastectomy becomes the appropriate step and robotic cancer surgery or conventional mastectomy is planned with reconstruction discussed alongside it.
• Intraoperative Assessment: High-volume centres perform frozen section analysis of the margin during surgery itself, letting the surgeon take more tissue immediately rather than waiting days for the final pathology report to confirm a problem.

Margin status goes to tumour board and the decision about what happens next is made collectively, and for more on how cancer surgery decisions are reached, our blog on cancer surgery covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every cancer resection where clear margins are the primary surgical objective. He heads Oncology Services across Karnataka and leads cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients dealing with positive margins or unclear pathology findings are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Cancer Surgery and Margins
2. National Institutes of Health — Surgical Margins in Oncology

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Breasts are made up of glandular tissue, fibrous connective tissue and fat. When glandular and fibrous tissue dominate over fat, the breast is considered dense. Around half of all women have it and it is entirely normal. The clinical significance comes from two things: dense tissue modestly raises cancer risk and it makes mammograms significantly harder to read because tumours and dense tissue look identical on the image.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “women with dense breasts aren’t in danger just because of the density itself. What matters is understanding how it affects screening and making sure the right imaging is being used to find what mammography alone might miss.”

Density is a radiological finding reported on mammography and most women don’t know their category until they read the report or ask their doctor directly.

• Four Density Categories: Radiologists grade breast density from almost entirely fatty at one end to extremely dense at the other using the BI-RADS classification system. The two higher categories are where supplemental screening becomes a clinical consideration worth discussing.
• What Causes It: Age, hormonal status, genetics and body weight all play a role. Pre-menopausal women tend to have denser breasts and density commonly reduces after menopause, though not predictably in every woman.
• The Mammogram Problem: Tumours appear white on mammography and so does dense glandular tissue. A cancer sitting inside dense breast tissue can be completely hidden by surrounding tissue, which is why standard mammography alone gives meaningfully less protection to women with breast cancer treatment risk factors and high density combined.
• Not the Same as Lumpy Breasts: Density is a radiological measurement, not something felt on examination. A woman with extremely dense tissue on imaging may feel no abnormality at all during self-examination or clinical assessment.

Most women don’t know their breast density unless they specifically ask for it to be reported, and asking is worth doing.

The short answer is yes, but the context behind that matters as much as the number.

• Real but Moderate Risk: Women in the two highest density categories have roughly two to four times the breast cancer risk of women with predominantly fatty breasts. That sounds significant but most women with dense breasts never develop cancer and density is one factor among many rather than a standalone predictor.
• Tumours Get Hidden: The masking problem is arguably more practically important than the risk elevation itself. Dense tissue obscures cancers that would be visible in a fatty breast, meaning interval cancers picked up between scheduled mammograms are more common in this group than in lower-density women.
• Supplemental Imaging Helps: Ultrasound finds additional cancers that mammography misses in dense breast tissue. MRI finds more still but is typically reserved for women who combine high density with other significant risk factors like a BRCA mutation or strong family history.
• Not a Reason to Panic: Most women with dense breasts never develop cancer and robotic cancer surgery or other treatment is only relevant if cancer is actually diagnosed. The point of knowing density is to screen smarter, not to create unnecessary anxiety about a normal anatomical variation.

Dense tissue is manageable with the right screening plan and for more on breast cancer surgery options when something is found, our blog on latissimus dorsi covers post-surgical reconstruction in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to breast cancer assessment including cases identified through dense breast supplemental screening. He heads Oncology Services across Karnataka and leads breast cancer surgery at KIMS Hospital, Bangalore, with originator credits for RABIT and over 25 published clinical studies. Women with dense breasts, elevated risk or abnormal screening findings are seen here with every decision going through tumour board review. Call +91 8104310753 to book your consultation.

Reference Links-

1. National Cancer Institute — Breast Density and Cancer Risk
2. World Health Organization — Breast Cancer Screening

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.

Ovarian cancer is called silent because it produces no specific early symptoms. Bloating, pelvic discomfort, frequent urination and early satiety are the four most commonly reported early indicators but all four are easily attributed to gut or urinary conditions. Most cases in India are diagnosed at Stage 3 or Stage 4. Detection before symptoms appear happens through incidental ultrasound findings, CA-125 testing in high-risk women and surveillance in confirmed BRCA1 or BRCA2 mutation carriers.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Ovarian cancer doesn’t announce itself. The women who get diagnosed early are almost always those in a surveillance programme or those whose general physician investigated persistent vague symptoms rather than treating them empirically.”

Detection relies on imaging, tumour markers and structured surveillance in high-risk women rather than population-wide screening which has not shown benefit in average-risk populations.

• Pelvic Ultrasound: Transvaginal ultrasound is the primary imaging tool for detecting adnexal masses and ovarian cancer treatment assessment at KIMS Hospital, Bangalore begins with transvaginal ultrasound combined with CA-125 for any woman presenting with persistent pelvic symptoms or an incidental adnexal finding on imaging.
• CA-125 Tumour Marker: CA-125 is elevated in most epithelial ovarian cancers but is not specific enough for population screening because it is also elevated in endometriosis, fibroids and pelvic inflammatory disease, making it most useful in combination with ultrasound findings rather than as a standalone test.
• BRCA Surveillance Protocol: Confirmed BRCA1 or BRCA2 mutation carriers who have not had risk-reducing salpingo-oophorectomy are offered six-monthly transvaginal ultrasound and CA-125 testing from age 30 to 35, recognising this surveillance has limitations but providing structured monitoring until preventive surgery is performed.
• Incidental Detection: A significant proportion of early ovarian cancers are detected incidentally on ultrasound ordered for an unrelated reason, underscoring the clinical value of investigating persistent non-specific pelvic or abdominal symptoms with imaging rather than empirical treatment.

No population-wide screening tool has demonstrated mortality benefit for ovarian cancer in average-risk women. Surveillance is reserved for confirmed high-risk individuals.

Structured ovarian cancer surveillance is clinically indicated in specific high-risk groups rather than recommended broadly.

• BRCA1 and BRCA2 Carriers: BRCA1 carriers face a 39 to 46 percent lifetime ovarian cancer risk and BRCA2 carriers face 12 to 20 percent and robotic cancer surgery or laparoscopic risk-reducing bilateral salpingo-oophorectomy between ages 35 and 40 for BRCA1 and 40 to 45 for BRCA2 remains the most effective intervention to reduce this risk.
• Strong Family History: Women with two or more first-degree relatives with ovarian or breast cancer, particularly diagnosed before age 50, warrant genetic counselling and BRCA testing before any surveillance programme is initiated rather than empirical surveillance without mutation confirmation.
• Lynch Syndrome Carriers: Lynch syndrome is associated with an 8 to 10 percent lifetime ovarian cancer risk and annual gynaecological review with transvaginal ultrasound is recommended from age 30 to 35 in confirmed carriers as part of the broader Lynch syndrome surveillance protocol.
• Persistent Vague Symptoms: Any woman over 50 with bloating, pelvic discomfort, early satiety or urinary frequency persisting for more than three weeks without a clear cause warrants immediate transvaginal ultrasound and CA-125 rather than empirical management for irritable bowel or urinary tract symptoms.

Early ovarian cancer detected through surveillance is surgically curable and for more on how specialist second opinions change cancer outcomes, our blog on second opinion covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to ovarian cancer surgery including cytoreductive surgery and HIPEC at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with ovarian masses, high-risk genetic profiles or ovarian cancer diagnoses are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

References

1. 1. National Cancer Institute — Ovarian Cancer Screening
   2. World Health Organization — Ovarian Cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.